Ranibizumab Via a Port Delivery System vs Intravitreal Injections in Patients With Neovascular AMD: Patient Preference and Treatment Satisfaction
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol 2022 Jun 16;[EPub Ahead of Print], MA Chang, A Kapre, D Kaufman, DR Kardatzke, M Rabena, S Patel, A Bobbala, S Gune, A Fung, G WallensteinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.